Litigation Details for BIOGEN INTERNATIONAL GMBH v. ZYDUS PHARMACEUTICALS USA, INC. (D.N.J. 2017)
✉ Email this page to a colleague
BIOGEN INTERNATIONAL GMBH v. ZYDUS PHARMACEUTICALS USA, INC. (D.N.J. 2017)
| Docket | ⤷ Sign Up | Date Filed | 2017-06-30 |
| Court | District Court, D. New Jersey | Date Terminated | 2017-10-31 |
| Cause | 15:1126 Patent Infringement | Assigned To | Brian R. Martinotti |
| Jury Demand | None | Referred To | Lois H. Goodman |
| Parties | BIOGEN INTERNATIONAL GMBH | ||
| Patents | 8,399,514 | ||
| Attorneys | GUILLERMO CARLO ARTILES | ||
| Firms | McCarter and English, LLP | ||
| Link to Docket | External link to docket | ||
Small Molecule Drugs cited in BIOGEN INTERNATIONAL GMBH v. ZYDUS PHARMACEUTICALS USA, INC.
The small molecule drug covered by the patent cited in this case is ⤷ Sign Up .
Details for BIOGEN INTERNATIONAL GMBH v. ZYDUS PHARMACEUTICALS USA, INC. (D.N.J. 2017)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 0000-00-00 | External link to document | |||
| 2017-06-30 | 1 | action for patent infringement of U.S. Patent Nos. 7,320,999 (“the ’999 patent”) and 8,399,514 (“the ’514…’514 patent”) arising under the patent laws of the United States, Title 35, United States Code, §§ 100…Zydus. FIRST COUNT FOR PATENT INFRINGEMENT (’999 PATENT) 12. Biogen realleges,… 13. The U.S. Patent and Trademark Office (“PTO”) issued the ’999 patent on January 22, 2008,… owner of the ’999 patent by virtue of assignment. 15. The ’999 patent expires on May 18, | External link to document | |
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
